Abaxis Announces Management Transition

                    Abaxis Announces Management Transition

PR Newswire

UNION CITY, Calif., Sept. 20, 2013

UNION CITY, Calif., Sept. 20, 2013 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS:
ABAX), a medical products company manufacturing point-of-care blood
instrumentation and consumables to the medical, research and veterinary
markets, announced today that Martin Mulroy has resigned his position as the
Company's chief commercial officer effective October 4, 2013 to pursue other
business and personal interests. In the interim, Don Wood, Chief Operations
Officer, will temporarily assume the responsibilities for leading Abaxis'
North American Animal Health (NAAH) business as the Company executes a
national search to appoint a successor. The search will encompass both
internal and external candidates.

Clint Severson, chairman and chief executive officer of Abaxis, said, "I want
to express my appreciation to Marty for his dedication and contributions in
growing our veterinary business over the past 15 years. Marty built a
successful platform in the veterinary business that will insure our continuing
success for many years. A broad national search will commence immediately to
hire a leader that can leverage that platform for the benefit of the Company
and, in turn, enhance shareholder value. I, along with the entire Abaxis team,
wish Marty the best in his future endeavors."

About Abaxis
Abaxis develops, manufactures, markets and sells portable blood analysis
systems for use in any veterinary or human patient-care setting to provide
clinicians with rapid blood constituent measurements. The system consists of a
compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of
single-use plastic discs, called reagent discs that contain all the chemicals
required to perform a panel of up to 13 tests on veterinary patients and 14
tests on human patients. The system can be operated with minimal training and
performs multiple routine tests on whole blood, serum or plasma samples. The
system provides test results in less than 12 minutes with the precision and
accuracy equivalent to a clinical laboratory analyzer. The veterinary business
also provides to the animal health and research market a line of hematology
instruments for point-of-care complete blood counts (CBC), a specialty
instrument to screen for and detect clotting disorders and to measure equine
fibrinogen levels, a handheld instrument for the rapid assessment of certain
critical care tests and rapid point-of-care tests for Heartworm infections in
dogs, Parvovirus, Lyme and Giardia. Abaxis, through its AVRL Division,
provides routine laboratory testing as well as specialty testing for
veterinarians nationwide. This state-of-the-art commercial laboratory will be
the hub of the Abaxis Veterinary Reference Laboratories (AVRL).
For more information, visit http://www.abaxis.com.

Forward Looking Statements
This press release includes statements that constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995 (the "Reform Act"), including but not limited to statements related to
Abaxis' cash position, financial resources and potential for future growth,
market acceptance and penetration of new or planned product offerings, and
future recurring revenues and results of operations. Abaxis claims the
protection of the safe-harbor for forward-looking statements contained in the
Reform Act. These forward-looking statements are often characterized by the
terms "may," "believes," "projects," "expects," "anticipates," or words of
similar import, and do not reflect historical facts. Specific forward-looking
statements contained in this press release or in Abaxis' conference call may
be affected by risks and uncertainties, including, but not limited to, those
related to risks related to transitioning our medical sales to Abbott, losses
or system failures with respect to Abaxis' facilities or manufacturing
operations, fluctuations in quarterly operating results, dependence on sole
suppliers, the market acceptance of Abaxis' products and services, the
continuing development of its products, required United States Food and Drug
Administration clearance and other government approvals, risks associated with
manufacturing and distributing its products on a commercial scale free of
defects, risks related to the introduction of new instruments manufactured by
third parties, risks associated with competing in the human diagnostic market,
risks related to the protection of Abaxis' intellectual property or claims of
infringement of intellectual property asserted by third parties and risks
related to condition of the United States economy. Readers should also refer
to the section entitled "Risk Factors" in Abaxis' annual report on Form 10-K,
recent quarterly reports on Form 10-Q and Abaxis' other periodic reports filed
with the United States Securities and Exchange Commission. Forward-looking
statements speak only as of the date the statements were made. Abaxis does
not undertake and specifically disclaims any obligation to update any
forward-looking statements.

Contact: Abaxis, Inc.            Lytham Partners, LLC
         Clint Severson          Joe Dorame, Robert Blum and Joe Diaz
         Chief Executive Officer 602-889-9700

SOURCE Abaxis, Inc.

Website: http://www.abaxis.com
Press spacebar to pause and continue. Press esc to stop.